Cybin Inc. (HELP) Shareholder/Analyst Call Prepared Remarks Transcript

Cybin Inc., doing business as Helus Pharma, convened its Annual General and Special Meeting of Shareholders on September 22, 2026. The excerpt covers meeting administration, shareholder voting procedures and attendee introductions, but provides no financial results, operational updates, shareholder-vote outcomes or guidance.

Analysis

This is not an investable fundamental catalyst: the available transcript is procedural and contains no clinical, regulatory, financing, commercialization, or guidance disclosure. For a pre-revenue CNS biotech, valuation is driven overwhelmingly by trial readouts, FDA interactions, cash runway, and dilution terms; an annual-meeting format alone does not alter any of those inputs. The near-term risk is not directionality from this event, but low-liquidity price noise if investors infer significance from management participation without accompanying material disclosure.

The relevant 1-3 month watch items are any post-meeting filings covering equity-plan authorization, reverse-split authority, director compensation, auditor language, or capital-raising capacity. Those governance items can matter materially if cash runway is short, because an expanded share reserve or financing mandate may raise the probability of discounted equity issuance and multiple compression before the next clinical catalyst. Conversely, absent a substantive update, the proper base case is no valuation impact; a trade thesis would require independently verified timing and probability-of-success data for the lead program.

Key Decisions for Investors

• No new directional position in HELP on this event; treat any same-day move without a concurrent filing or clinical update as non-fundamental and avoid chasing it.
• Set a filing alert for AGM voting results and subsequent SEDAR+/SEC disclosures over the next 5 trading days. Review specifically for share-capital, equity-incentive, reverse-split, and financing authorities before assessing dilution risk.
• For existing HELP exposure, maintain a tight event-risk framework through the next disclosed clinical or regulatory milestone: reduce if financing is announced at a material discount to market or if reported cash runway does not extend beyond the next major readout.
• Do not establish an options position unless open interest and bid-ask spreads support execution; missing liquidity data makes any options recommendation inappropriate.